Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Schizophrenia
Interventions: Luvadaxistat, Matching Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Gaithersburg, Maryland

Conditions: Human Immunodeficiency Virus
Interventions: 10-1074-LS, 3BNC117-LS; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Pain
Interventions: Suzetrigine (SUZ), HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 8 more

Conditions: Down Syndrome
Interventions: Placebo, RO5186582; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more

Conditions: Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
Interventions: Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care; Drug
Lead sponsor: APR Applied Pharma Research s.a.; Other
Eligibility: 18 Years to 100 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Fullerton, California • Irvine, California • Miami, Florida + 6 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Azacitidine, Venetoclax, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 24
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: UC (Urothelial Cancer)
Interventions: Pembrolizumab, Epacadostat, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 24
States / cities: Chandler, Arizona • Orange, California • San Francisco, California + 19 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis
Interventions: Pre-filled Auto-injector Containing Placebo; Device
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Miami, Florida • Duncansville, Pennsylvania

Conditions: Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
Interventions: Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate; Procedure · Drug · Combination Product
Lead sponsor: Gary Van Guilder; Other
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Gunnison, Colorado

Conditions: Systemic Lupus Erythematosus, Arthritis
Interventions: mycophenolate mofetil, placebo; Drug · Other
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 14 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Ulcerative Colitis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 73 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 10
States / cities: Anaheim, California • La Jolla, California • Oceanside, California + 7 more

Conditions: Healthy Participants
Interventions: Alpha-cyclodextrin, Placebo, Triolein radiolabeled with 100 microcuries of 3^Hydrogen, Tripalmitin radiolabeled with 20 microcuries of 14^Carbon; Dietary Supplement · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Golimumab, Methotrexate, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 20
States / cities: Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more

Conditions: Alzheimer s Disease
Interventions: Terazosin (Hytrin), Placebo; Drug · Other
Lead sponsor: Qiang Zhang; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: NSCLC (Non-small Cell Lung Carcinoma)
Interventions: Ruxolitinib, Placebo, Pemetrexed, Cisplatin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 30
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Fresno, California + 27 more

Conditions: Age-Related Memory Disorders
Interventions: Transdermal nicotine patch, Placebo transdermal patch; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Durham, North Carolina • Burlington, Vermont

Conditions: Pain, Osteoarthritis
Interventions: APIC-CF, 4 cc, APIC-CF, 2 cc, Placebo Comparator: Saline; Device · Other
Lead sponsor: Cytonics Corporation; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Townsend, Maryland

Conditions: Lung Cancer
Interventions: Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Pemetrexed; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Anaheim, California • Wichita, Kansas

Conditions: Major Depression, Temporal Lobe Epilepsy
Interventions: escitalopram, placebo; Drug
Lead sponsor: Conrad, Erich J., M.D.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
Interventions: Romosozumab Prefilled Syringe, Placebo, Zoledronic acid 5 mg; Drug
Lead sponsor: Karen Klahr Miller, MD; Other
Eligibility: 20 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic HBV Infection
Interventions: EDP-514, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 11
States / cities: Coronado, California • Los Angeles, California • San Diego, California + 8 more

Conditions: Bunion, Post-operative Pain
Interventions: Local anesthetic injection of CPL-01, Naropin, 0.5% Injectable Solution, Placebo, Morphine rescue medication, Acetaminophen rescue medication, Oxycodone rescue medication, Bunionectomy; Drug · Procedure
Lead sponsor: Cali Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Phenylketonuria
Interventions: JNT-517 Suspension, Placebo Suspension, JNT-517 Tablet, Placebo Tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Gainesville, Florida • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Ventral Hernia
Interventions: Alvimopan, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

Determining Lipid Content in Stool After Alpha-cyclodextrin

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Terazosin And Metabolic Engagement in Alzheimer's Disease

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Nicotine Treatment of Mild Cognitive Impairment (MCI)

APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

CPL-01 in the Management of Postoperative Pain After Bunionectomy

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair